(24/7 MARKET NEWS) – Sera Prognostics Inc. (NASDAQ: SERA) reported, this morning, top-line results from the AVERT PRETERM TRIAL (Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls), conducted at ChristianaCare in Wilmington, Delaware. Sera Prognostics stated that its PreTRM® test-and-treat strategy demonstrated statistically and clinically significant improvement in neonatal health outcomes and hospital length-of-stay
Sera Prognostics is at $1.66, up $0.35 (26.71%), on trading volume of 670 thousand premarket shares.
Its 52-week trading range is $1.10 to $7.215. It’s cleared several months of resistance and is set up for a potential run higher.
View original content: https://www.prnewswire.com/news-releases/sera-prognostics-announces-positive-top-line-data-from-avert-preterm-trial-301747486.html
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
